Thanks for visiting Scientific Computing World.

You're trying to access an editorial feature that is only available to logged in, registered users of Scientific Computing World. Registering is completely free, so why not sign up with us?

By registering, as well as being able to browse all content on the site without further interruption, you'll also have the option to receive our magazine (multiple times a year) and our email newsletters.

Informatics upgrade aids enzyme drug development

Share this on social media:

The University of Texas MD Anderson Cancer Center has upgraded its Pathway Studio installation with Ariadne's ChemEffect drug-centric module, helping research into enhancing the therapeutic utility of the enzyme drug L-Asparaginase (L-ASP).

Dr Phil Lorenzi, supervisor of laboratory and research, Department of Bioinformatics and Computational Biology, who is heading research efforts for this project noted: 'L-ASP is a standard component of chemotherapy regimens for leukemia and is also being tested against solid tumours, but efficacy is observed in only a subset of patients. We're looking for protein and small molecule biomarkers that predict L-ASP response and for small molecules that exhibit synergistic anticancer activity with L-ASP.'

Dr John Weinstein, chair of the department and principal investigator of the project, adds: 'Together with data from siRNA screening and metabolomic profiling experiments, Pathway Studio and ChemEffect will facilitate a systems-wide approach to prioritising candidate biomarkers and potentially synergistic drug combinations. If successful, an advantage of trying to re-position approved drugs, rather than bring a new one to the table, is that we don't have to wait 14 years or have a billion dollars in spare change to make it happen.'

'Our laboratory employs a systems pharmacology approach to identifying novel mechanisms of action, biomarkers that predict drug effect, and synergistic combination therapies,' states Lorenzi. 'Pathway Studio helps us integrate those strategies.'